echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: A novel small molecule thymidylate synthase inhibitor CT900 in the treatment of high-grade serous ovarian cancer

    Clin Cancer Res: A novel small molecule thymidylate synthase inhibitor CT900 in the treatment of high-grade serous ovarian cancer

    • Last Update: 2022-10-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CT900 is a novel small molecule thymidylate synthase inhibitor that binds to the α-folate receptor (α-FR), which in turn can be selectively taken up by tumors overexpressing α-FR


    The study used a 3+3 dose escalation design


    A total of 109 patients were enrolled, 42 in the dose-escalation cohort and 67 in the expansion cohort



    In the expansion cohort, the overall response rate (ORR) was 14/64 (21.


    In summary, the recommended Phase II dose/scheme is 12 mg/m2/q2Wk


     

    Original source:

    Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.